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ABSTRACT 
Aims: Gastrointestinal symptoms are common during chemotherapy, but underlying 
disturbances in gut function and impact on daily life are unclear. This study investigates gut 
function in a heterogenous group of cancer patients with gastrointestinal symptoms during 
chemotherapy, and the relation with anabolic response, muscle health, and daily 
functioning. 
Methods: In 16 patients with solid tumors (mostly stage III+IV) undergoing chemotherapy 
(T) and 16 healthy matched controls (H), small intestinal membrane integrity was measured
by urine sugar tests. Protein digestion, absorption and anabolic response to a conventional 
protein supplement were analyzed by stable tracer methods. Muscle mass and strength and 
daily functioning were assessed.  
Results: 
Eighty-one percent of T reported gastrointestinal symptoms. Small intestinal membrane 
permeability was similar, but active glucose transport lower in T (T: 35.5 ± 3.4% vs. H: 48.4 ± 
4.7%, P=0.03). Protein digestion and absorption tended to be lower in T (0.67 ± 0.02 vs. 0.80 
± 0.04, P=0.08). Net protein anabolic response to feeding was comparable, although lower 
in cancer patients with recent weight loss. Gut permeability negatively correlated to 
handgrip strength, global health and physical functioning and active transport capacity 
positively correlated to global health in T. 
Conclusions: 
Advanced cancer patients with gastrointestinal symptoms during chemotherapy, particularly 
those with recent weight loss, show signs of impaired gut function, negatively affecting 
muscle health, daily functioning, and anabolic response to feeding. 
<PE-FRONTEND> 
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INTRODUCTION 
Chemotherapy is one of the most common treatments for advanced cancer. Although 
chemotherapy can prolong life and improve treatment outcomes, it has many side effects.  
As the mucous membranes of the gut have a high cellular turnover, chemotherapy damages 
the mucosa, which often leads to symptoms such as vomiting, diarrhea and alimentary 
toxicity (mucositis) (1,2). Gut toxicity following chemotherapy causes significant morbidity 
and mortality (1). For instance, diarrhea is reported in 10 to 40% of patients receiving 
chemotherapy (1,3). It is a major chemotherapy dose-limiting factor (1) and associated with 
a reduced quality of life (3). Mucositis, defined as “a complication of some cancer therapies 
(e.g. chemotherapy) in which the lining of the digestive system becomes inflamed” (4), 
increases the risk of mortality, bleeding, infection, prolonged antibiotic use, longer length of 
hospital stay and poorer quality of life (QoL) (5). Mucositis happens in 20-40% of the 
patients undergoing conventional chemotherapy and in 80% of patients receiving high 
chemotherapy doses (6,7). These studies indicate that many cancer patients, independent 
of cancer type, are affected by gastrointestinal symptoms during chemotherapy. However, 
the mechanisms behind the chemotherapy induced gut symptoms remain underexplored.  
Chemotherapy causes a disruption of the microbiome (8), leading to acute gut inflammation 
and gastro-intestinal mucositis (7). Chemotherapy-induced diarrhea is thought to be the 
consequence of a multifactorial process involving gut motility, decreased transit time and 
elevations in gut inflammation, alterations in the gut microflora and transient lactose 
intolerance (1). Based on research in inflammatory bowel disorders, mucosal barrier 
dysfunction and tight junction defects were proposed to contribute to chemo-induced 
diarrhea development through leak-flux mechanisms (1). In cancer, several preclinical and 
clinical studies have investigated mucosal barrier function after administration of cytotoxic 
agents, and consistently found increased intestinal permeability, with some speculating on 
tight junction involvement (1). 
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As a consequence of chemo-induced gut toxicity, the digestion of nutrients can be impaired 
in patients undergoing chemotherapy, which may cause muscle wasting and physical 
impairment. It has been shown that weight loss in cancer patients cannot fully be explained 
by reduced dietary intake and persists even when protein and energy intakes have 
normalized (9). Evidence exists that advanced cancer patients are characterized by anabolic 
resistance to a complete (protein) meal (10) despite a preserved anabolic response to 
dietary free essential amino acids (11). This suggests an impaired digestion and absorption 
capacity.  
We recently developed a comprehensive panel of methods to measure gut function in 
disease states. We showed that the labeled phenylalanine and spirulina test (12), measuring 
the combined action of intraluminal, and after absorption the intracellular, breakdown of 
the spirulina protein and peptides, provides a good overall measure of protein digestion and 
absorption of a protein meal. The anabolic response to a meal can be assessed by stable 
isotope methodology (13,14) and subsequently be adjusted for potential disturbances in 
protein digestion and absorption. In addition, small intestinal integrity (membrane 
permeability and active glucose transport), and enterocyte mass and function can be 
assessed by sugar tests (5,15).  
This study investigates whether gut function, using a panel of methods, is impaired in a 
heterogenous group of advanced cancer patients with gastrointestinal symptoms during 
chemotherapy and whether it affects muscle health, daily functioning, and anabolic 
response to feeding. 
MATERIALS AND METHODS 
Subjects 
We studied 16 patients with advanced cancer and 16 gender-, age- and BMI-category 
matched healthy subjects from the MEDIT trial (MEtabolism of Disease with Isotope Tracers) 
(13). The basal protein and amino acid kinetics have been published previously (16). All 
subjects provided written informed consent and the study was approved by the Institutional 
Review Board of Texas A&M University (reference number: 2012-0504) and registered in the 
Clinical Trial Registration (reference number: NCT01871350). The study took place at the 
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Clinical Research Unit of the Center for Translational Research on Aging and Longevity, 
Texas A&M University.  
General and disease characteristics 
For patients with cancer, information on tumour type, histology, stage, laboratory 
parameters, days since diagnosis or recurrence, days since last chemotherapy 
administration, chemotherapy regimen and concurrent RT was collected from medical 
records. Karnofsky Performance Score (17,18) and unintentional weight loss in the past 
month was obtained. Patients completed the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (EORTC-QLQ-C30)(19).  
Body composition and physical function 
Body weight and height were assessed by a digital beam scale and stadiometer, respectively 
and Body Mass Index was calculated (16). Total fat mass, fat-free mass (FFM), and 
appendicular skeletal muscle mass were measured by Dual-Energy X-ray Absorptiometry 
and standardized for height (kg/m2) (13). We assessed habitual dietary intake by 24-hour 
dietary recall (13), and physical activity using the Physical Activity Scale for the Elderly 
questionnaire (20). 
Muscle function 
Respiratory and skeletal muscle function were assessed as described before (16). 
Respiratory muscle tests included maximal expiratory pressure (MEP) and maximal 
inspiratory pressure (MIP) using a hand-held mouth pressure device (Micro Respiratory 
Pressure Meter (RPM) (21). Skeletal muscle function was assessed by peak leg force using 
Kin Com isokinetic dynamometry (Isokinetic International, Chattanooga, TN, USA) (22) and 
handgrip strength by Vernier dynamometry (Vernier Software and Technology, Beaverton, 
OR, USA) respectively (23). 
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Comprehensive Panel of Gut Function Measurements 
After enrollment, healthy subjects or patients with cancer returned for the 8-h study day in 
the postabsorptive state (Supplementary Figure 1).  
Small intestinal membrane integrity 
Small intestinal membrane integrity was measured by urinary recovery of orally ingested 
inert sugars that are not metabolized by the body. After the collection of baseline urine 
samples to detect natural sugar concentrations, subjects ingested 0.5 g L-Rhamnose (R), 7.5 
g Lactulose (L) and 70 mg 3-O-Methyl-D-Glucose (3-OMG) diluted in 70 mL water (t=0h). 
Urine was collected over 7 hours and kept on ice, after which the total volume passed was 
recorded, and aliquots of 500 µl were stored at -80 C until analysis was performed.  
Lactulose is a larger non-metabolizable sugar that cannot be digested in the small intestine 
and only insignificant amounts are absorbed across the intestinal mucosal barrier under 
normal conditions. L-Rhamnose is a sugar that is passively absorbed across the intestinal 
mucosal barrier. 3-OMG is a larger non-metabolizable sugar with ATP-dependent absorption 
across the intestinal mucosal barrier. Since lactulose enters the body on a paracellular route 
and rhamnose by non carrier-mediated transcellular transport, urinary lactulose/rhamnose 
ratio is an indicator for the permeability of the small intestinal membrane and, thus, small 
intestinal barrier function {Lutgens, 2005, 191-9}. The urinary recovery of 3-OMG [%] is an 
indicator for active carrier-mediated glucose transport and, thus, for intestinal absorption 
capacity {Lutgens, 2005, 191-9}. 
Protein digestion and absorption 
Protein digestion and absorption and anabolic response to a high protein meal were 
measured by stable tracer methods (12). We inserted a catheter into an antecubital vein for 
continuous stable tracer infusion and a second catheter into a superficial dorsal vein of the 
contralateral hand for blood sampling. The hand was placed in a thermostatically controlled 
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading 
process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jpen.1941.  
This article is protected by copyright. All rights reserved. 
hot box to obtain arterialized-venous blood (24). We collected baseline venous blood 
samples to determine the natural enrichments of PHE and TYR. From t=2h to t=7h, a primed 
and constant, continuous stable tracer infusion containing L-[ring-2H5]‑PHE and L-[
13C9,
15N]-
TYR was administered (0.177 (0.038) µmol/kg FFM/min L-[ring-2H5]-PHE and 0.0056 (0.0012)
µmol/kg FFM/min L-[13C9,
15N]-TYR). The prime contained 75% of the hourly infusion rate. At
t=4h, participants drank a complete high protein meal within 5 to 10 minutes, the 
commercially available BOOST High Protein supplement (237 mL, 15 g protein, 6 g fat, 33 g 
carbohydrates) (Société des Produits Nestlé S.A., Vevey, Switzerland), enriched with free L-
[1-13C]-PHE (76.5 mg) and uniformly labeled 15N-Spirulina (1,471.15 mg) containing L-[1-15N]-
PHE. All stable tracers were purchased from Cambridge Isotope Laboratories (Woburn, MA, 
USA). Arterialized-venous blood was sampled 15 times from t=2 to t=7.5h for analysis of 
concentrations and tracer-tracee ratios (TTR) of amino acids, assessed by LC-MS/MS 
(Supplementary Figure 1).  
Biochemical analysis 
Arterialized-venous blood was put in Li-heparinized or EDTA tubes (Becton Dickinson 
Vacutainer system, Franklin Lakes, New Jersey, USA), immediately put on ice to minimize 
enzymatic reactions, and centrifuged (4°C, 3120 x g for 5 min) to obtain plasma. A part of 
the plasma was aliquoted into tubes with 0.1 vol of 33% (w/w) trichloroacetic acid or a 
residue after evaporation of 0.17 vol of 33% (w/w) 5-sulfosalicylic dihydrate, and then 
vortexed for denaturation of proteins. Samples were instantly frozen and stored at -80°C 
until further analysis. Tracer enrichments [tracer:tracee ratio (TTR)] and plasma amino acid 
concentrations were analyzed by LC-MS/MS by isotope dilution as previously reported 
(13,25). All samples were analyzed batchwise. Urine concentrations of inert sugars were 
obtained by LC-MS/MS and L/R and 3-OMG/R ratios were calculated as described above 
(5,15,26,27). 
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Calculations of metabolic parameters 
The urinary recovery of sugars was corrected for the median of baseline (background) sugar 
concentrations and expressed as the percentage of oral intake. To measure small intestinal 
non carrier-mediated permeability and active carrier-mediated transport, respectively the 
lactulose/rhamnose ratio and urinary 3-OMG recovery rate [%] was calculated. 
Protein digestion and absorption were analysed by first calculating the ratio of the whole 
body rate of appearance of [1-15N]-PHE from 15N-spirulina to the orally provided free [1-13C]-
PHE, which does not require digestion before absorption. Therefore, spirulina degradation 
ratio can be measured by subsequently dividing this plasma ratio by the ratio of [1-15N]-PHE 
to [1-13C]-PHE in the protein meal (12).  
We calculated protein kinetic measures (whole-body protein synthesis, breakdown, and 
anabolic response (=protein synthesis – breakdown)) from the isotope enrichments in the 
postabsorptive and postprandial state, under steady-state conditions (28–30). To correct 
anabolic response for protein digestion and absorption, it was not assumed that protein 
from the meal was completely digested, but the amount of PHE in the protein meal was 
multiplied by the spirulina degradation ratio. Anabolic response was in both cases corrected 
for splanchnic extraction. Splanchnic extraction is the fraction of orally ingested free 
phenylalanine that does not reach the systemic circulation because it is either not absorbed 
by the enterocytes or metabolized by the intestine and liver during its first pass (28–30). 
Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM). Population 
characteristics and baseline measurements were compared with the use of unpaired 
Student’s t-tests. Alternatively, categorical values were compared with the use of the 
Pearson Chi-Square tests. Bivariate Pearson’s correlation analysis was used to measure the 
linear correlation between continuous variables. The statistical package within Graphpad 
Prism (Version 8.0.1) and SPSS (version 26) were used for data analysis. The level of 
statistical significance was set at P<0.05. 
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RESULTS 
We enrolled 16 patients with solid tumors undergoing chemotherapy (T) and 16 age- and 
sex matched healthy controls (H). The subjects had various types of solid tumors, mostly 
stage III (n=8, 50%) and IV (n=7, 44%), one subject had stage IIb (6%) (Table 1). Thirty-eight 
percent (n=6) had colorectal cancer and all but one patient received platinum-based 
chemotherapy. Fifty percent of patients received additional leucovorin and 5-fluorouracil (5-
FU). One-fourth of patients (n=4) had not had any chemotherapy before enrollment; 3 (19%) 
had undergone 1 chemotherapy cycle, and 5 patients (31%) 2 cycles. Another one-fourth  
(n=4) had undergone 3 or more chemotherapy cycles before enrollment. The majority 
(n=15, 81%) reported one or more gastrointestinal symptoms: nausea and vomiting (n=5, 
31%), constipation (n=7, 44%), diarrhea (n=74%) or appetite loss (n=7, 44%). Blood 
inflammatory markers (CRP and albumin) showed low-grade systemic inflammation.  
Results on nutritional status and muscle strength have been published previously (16). Six 
subjects with cancer reported more than 5% weight loss in the past months (37.5%). No 
significant differences were found between T and H groups in BMI, fat-free mass index, 
energy and protein intake. Physical activity level assessed by the PASE questionnaire was 
slightly lower in cancer, however this difference was not significant (C: 135.0 ± 25.1 vs. H: 
165.1 ± 20.7, P=0.36). Maximal inspiratory pressure (C: 72.2 ± 7.6 vs. H: 115.8 ± 10.5) and 
leg extension strength (C: 252.6 ± 29.5 vs. H: 374.1 ± 36.1) were lower in patients with 
cancer (P< 0.01)(16).  
Small intestinal membrane integrity 
Average urinary L/R ratios and 3-OMG/R ratios were not significantly different between 
groups. Urinary 3-OMG% was lower in T (T: 35.5 ± 3.4% vs. H: 48.4 ± 4.7%, p=0.03), 
indicating less capacity for active transport, as 3-OMG% reflects ATP-dependent absorption 
of this sugar across the intestinal mucosal barrier (Figures 1, 2, 3).  
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading 
process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jpen.1941.  
This article is protected by copyright. All rights reserved. 
L/R ratios in subjects with cancer correlated negatively with handgrip strength (r=-0.544, 
P=0.029), suggesting that more gut leakage is associated with poorer muscle strength. 
Similarly, L/R ratios were negatively correlated with global health (r=-0.640, P=0.008) and 
physical function (r=-0.550, P=0.027). We found a positive correlation between 3-OMG% 
and global health (r=0.595, P=0.015), suggesting that a higher active transport capacity is 
associated with a better global health.  
Protein digestion and absorption 
Protein digestion capacity and the protein anabolic response to a meal were not significantly 
different between T and H (Table 3). Protein digestion capacity was not different in subjects 
with cancer with a lower Karnofsky Performance Score (≤70), higher stage of cancer (IV vs. II 
and III), concurrent radiotherapy, ≥5% weight loss, 1 or more hospital admission in the past 
year. No significant correlations were found between protein digestion capacity and days 
since recurrence, energy intake, protein intake, fat-free mass index or physical activity score 
(PASE).  
The Spirulina-[U-15N] degradation ratio (marker of protein digestion capacity), tended to be 
lower in cancer subjects (0.67 ± 0.02 vs. 0.80 ± 0.04, P=0.08), and was positively correlated 
to muscle mass index (r: 0.532, P=0.034) and appendicular skeletal muscle mass (r: 0.532, 
P=0.034). The uncorrected net anabolic response to the meal was higher in cancer subjects 
(82.2 ± 5.1 vs. 66.6 5.2 µmol/kg ffm/3h, P=0.04), but comparable between cancer and 
healthy subjects after correction for protein digestion capacity. The anabolic response 
corrected for protein digestion capacity was lower in weight-losing patients (≥5% weight 
loss: 34.2 ± 4.2 vs. <5% weight loss: 47.4 ± 2.7,  P=0.015), and tended to be lower in patients 
with stage IV (IV: 36.8 ± 3.3 vs. II and III: 46.8 ± 3.7, P=0.064), as was splanchnic extraction 
(IV: -0.107 ± 0.031 vs. II and III: 0.043 ± 0.053, P=0.04). 
Splanchnic extraction of phenylalanine was comparable between cancer and healthy 
subjects (Table 3). However, splanchnic extraction was negatively correlated to 
appendicular skeletal muscle index (r: -0.522, P=0.038), and leg flexion strength (r: -0.502 
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P=0.048), indicating that a higher splanchnic extraction is associated with lower muscle 
mass and muscle strength.  
DISCUSSION 
This study investigated impairments in gut function and protein anabolic response to 
feeding in patients with solid tumors experiencing gastrointestinal symptoms during 
chemotherapy. Using a comprehensive panel of methods, we found early signs of a leaky 
gut and a trend towards impaired protein digestion and absorption in patients with cancer 
as compared to age- and gender matched healthy controls. Although small intestinal 
dysfunction did not reduce the protein anabolic response to feeding in cancer, intestinal 
dysfunction in these advanced cancer patients undergoing chemotherapy was associated 
with impaired muscle health and reduced daily functioning (as reflected by lower hand and 
leg muscle strength and self-reported global health, physical function and physical activity).  
Small Intestinal Barrier Function and Active Carrier-Mediated Transport  
In the current study, the lactulose/rhamnose ratio, as marker of passive transport, in 
patients with cancer was not different from the studied healthy controls, but higher than 
published normal values. However, urinary 3-OMG recovery rate was decreased in patients 
with cancer, suggesting a malfunction of the active carrier-mediated transport in 
enterocytes. L/R ratios in subjects with cancer correlated negatively with handgrip strength, 
global health and physical function, suggesting that more gut leakage, the lower grip 
strength and reported quality of life. Our findings are not completely in line with the small 
number of studies that have investigated gut permeability in the past. Wardill et al 
summarized 6 human studies documenting increased lactulose/rhamnose ratios in patients 
with cancer on various chemotherapy drugs (1). One of the explanations of the different 
findings could be the chemotherapy agents that were used in these studies, e.g. 
cyclophosphamide and melphalan, agents known for causing significant gut toxicity (31). In 
the present study, none of these agents were used in the cancer group. 
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An increased small and large intestinal permeability and a reduced active carrier-mediated 
transport have also been reported in chronic heart failure and COPD patients (32–34). An 
increased intestinal permeability might result in bacterial translocation and endotoxin 
release causing an inflammatory immune activation (33). Although the cancer patients were 
characterized by low-grade systemic inflammation (average CRP: 8.6 mg/L), we were unable 
to find a relationship between CRP levels and small intestinal permeability or other gut 
function parameters. In addition, certain co-medications might negatively affect gut 
integrity (34), for instance steroids that are administered in conjunction with chemotherapy. 
Protein Digestion and Absorption 
Protein digestion and absorption were investigated by a novel dual-tracer method and 
tended to be lower in the cancer group. Although the anabolic response to a meal on group 
level was not different between the cancer and control subjects, lower values were found in 
those patients who had recently lost more than 5% of their body weight and in those with 
stage IV disease. In these subgroups, splanchnic extraction of dietary amino acids was also 
elevated. In other words, weight-losing patients and those with metastatic disease had a 
lower anabolic response to food, at least in part related to the higher first pass extraction of 
amino acids by the splanchnic area, resulting in lower amino acid availability in the systemic 
circulation for muscle build-up. In line, splanchnic extraction was negatively correlated to 
muscle mass, muscle strength and physical activity.  To our knowledge, this confirms that 
gut dysfunction plays an important role in the explanation of the observed weight loss and 
impaired muscle health and physical functioning in cancer patients undergoing 
chemotherapy. Although protein intake was similar between patients with cancer and 
healthy controls, reaching around 1.06 g/kg/d protein, this level of protein intake is 
probably not sufficient to maintain muscle mass, also taking into account gut impairments. 
Easy digestible (hydrolyzed) proteins with high levels of essential amino acids are important 
for this patient population with high protein requirements and signs of gut impairment.  
A limitation of the study is the inability to differentiate the effects from cancer and 
chemotherapy on gut function in the human clinical setting, as both factors are taking place 
at the same time. It was not feasible to examine these subjects also prior to chemotherapy 
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due to the short time period between diagnosis and the start of chemotherapy. In order to 
unravel the individual and combined effects of chemotherapy and cancer on gut function, 
animal research is required. Moreover, due to the heterogeneity of the patient population 
with regard to tumour type, chemotherapy regime, and the duration that patients had 
received chemotherapy, our data need to be interpreted with caution. However, we showed 
that in this mixed group of cancer patients with solid tumors and different chemotherapy 
treatments, nearly all patients experienced gastrointestinal symptoms and a relatively 
homogenous gut function profile was observed. 
 In conclusion, patients with advanced cancer and gastrointestinal symptoms during 
chemotherapy show early signs of a leaky gut and impaired digestion, which is associated 
with impaired muscle health and some markers of daily functioning. Future research is 
required to explore interventions that can compensate for the increased maldigestion and 
splanchnic extraction, in order to maintain muscle mass, muscle strength, and physical 
function during chemotherapy.  
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Table 1. Characterization of the individual patients with cancer 
Table 2. Whole body prandial protein metabolism after intake of a high-energy, high protein 
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Figure 2. 3-OMG/R ratios in healthy controls and cancer patients 
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Figure 3. 3-OMG (%) in healthy controls and cancer patients 
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Table 2. Whole body prandial protein metabolism after intake of a high-energy, high protein 
meal in healthy controls and cancer patients 









Protein synthesis (µmol/kg ffm/3h) 
ffpheps 
330.4 (13.1) 359.0 (9.8) 0.09 
Endogenous protein synthesis, corrected for 
15N-spirulina (µmol/kg ffm/3h) 
ffpheendo 
263.8 (10.9) 276.8 (9.9) 0.39 
Net protein synthesis (µmol/kg ffm/3h), 
uncorrected 
ffphenetps 
66.6 (5.2) 82.2 (5.1) 0.04 
Net protein synthesis, corrected for 15N-
spirulina (µmol/kg ffm/3h) 
ffphenetpsspir 
47.1 (6.0) 42.4 (2.8) 0.49 
15N-Spirulina degradation (ratio) 
ff15nspir 
0.80 (0.04) 0.67 (0.02) 0.08 
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